Apotex Pty Ltd ACN 096 916 148 and Sanofi‑Aventis Australia Pty Ltd and Sanofi‑Aventis Deutschland GmbH and Aventisub Ii Incorporated

The dispute before the High Court of Australia concerned allegations of patent infringement and invalidity. Apotex Pty Ltd (Apotex) was the applicant, and Sanofi-Aventis Australia Pty Ltd, Sanofi-Aventis Deutschland GmbH, and Aventisub II Incorporated (Sanofi) were the respondents. The proceedings arose from Apotex's proposed importation and sale of a pharmaceutical product, which Sanofi alleged infringed its patent rights.

The High Court was required to determine whether Sanofi's patent was valid and, if so, whether Apotex's proposed product infringed that patent. Central to the dispute was the interpretation of the patent claims and the assessment of whether the product manufactured by Apotex fell within the scope of those claims, considering the doctrine of equivalents. The validity of the patent also hinged on whether it met the requirements of novelty and inventive step in light of prior art.

The Court's reasoning involved a detailed analysis of the patent specifications and the relevant provisions of the *Patents Act 1990* (Cth). It applied established principles of patent law concerning claim construction, infringement, and validity. The Court considered the evidence presented by both parties regarding the technical aspects of the pharmaceutical products and the prior art. The application of the doctrine of equivalents was crucial in determining infringement, requiring an assessment of whether Apotex's product achieved substantially the same result in substantially the same way as the patented invention, despite minor differences.

The High Court ultimately found in favour of Sanofi, upholding the validity of the patent and finding that Apotex's proposed product infringed the patent. Consequently, the Court made orders restraining Apotex from infringing Sanofi's patent rights.